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Abstract 
Introduction: The introduction of proton pump inhibitors (PPIs) into clinical 
practice has greatly improved our therapeutic approach to acid-related diseases 
for their efficacy and safety.  
Areas Covered:The following evidence-based indications for PPI use are 
acknowledged by many scientific societies : treatment of the various forms and 
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complications of gastroesophageal reflux disease, eradication of H. pylori 
infection in combination with two or more antibiotics, short- and long-term 
therapy of H. pylori-negative peptic ulcers, healing and prevention of 
NSAID/COXIB-associated gastric ulcers, co-therapy with endoscopic procedures 
to control upper digestive bleeding and medical treatment of Zollinger Ellison 
syndrome.  
Expert Commentary:Despite the above well defined indications, however, the 
use of PPIs continues to grow every year in both western and eastern countries 
and the endless expansion of PPI market has created important problems for 
many regulatory authorities for two relevant features : the progressive increase 
of the costs of therapy and the greater potential harms for the patients. The 
major reasons for the misuse of PPIs are the prevention of gastro-duodenal 
ulcers in patients without risk factors and the stress ulcer prophylaxis in non-
intensive care units, steroid therapy alone, anti-platelet or anti-coagulant 
treatment in patients without risk of gastric injury and the overtreatment of 
functional dyspepsia.  
 
Key words : Proton pump inhibitors (PPIs); acid-related diseases; appropriate 
use; misuse; overprescription. 
 
1. Introduction 
 The study of gastric acid secretion has attracted the interest of both physiologists and 
physicians for many years, because a great number of diseases of the upper gastrointestinal 
(GI) tract are related to dysfunctions in acid production. Many investigations have 
documented that gastric acid is produced by both resting and meal-stimulated parietal cells in 
the stomach, following neurocrine, paracrine and endocrine stimulation by various 
substances, such as acetylcholine, histamine or gastrin, which bind to their specific receptors 
placed on the baso-lateral membrane of the above cells (1). Thereafter, intracellular second 
messenger systems are activated leading to protein kinase formation and activation of H+/K+ 
ATPase enzyme (proton pump), which fuse with the secretory canaliculus of the parietal cell 
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resulting in acid production, whereby intracellular hydrogen ions are exchanged for 
extracellular potassium ions (2). Once acid is produced, the lower luminal intragastric pH 
stimulates a feedback mechanism to maintain appropriate homeostatic control of acid 
secretion. This response is mediated primarily by paracrine release of somatostatin from 
gastric antral D cells, which inhibit G cell production of gastrin and enterochromaffin-like 
(ECL) formation of histamine in order to reverse the stimulus for acid secretion (3).  
In relation to the above complex physiologic, mainly receptorial, mechanisms for acid 
secretion, drug research in this area has focused on the development of compounds able to 
increase the pH of gastric contents and the synthesis of many powerful inhibitors of gastric 
acid secretion has allowed us to control adequately acid-related diseases, thus minimizing the 
role of surgery in this field. 
 In fact, antisecretory therapy has advanced dramatically since the introduction of 
cimetidine in the mid-1970s and subsequently other molecules pertaining to this class of acid-
lowering agents have been added to the market, such as ranitidine, famotidine, nizatidine and 
roxatidine. All these drugs are able to block the histamine2 receptor on parietal cells, which is 
one of the three main pathways regulating gastric acid secretion, and this effect reduces 
hydrogen ion release into the stomach. However, H2-receptor antagonists (H2-RAs) have 
several important limitations, in that they present a relatively short duration of action, which 
ranges  approximately from 4 to 8 hours and therefore multiple daily doses of them are 
required, but even this repeated administration does not permit to obtain a complete control 
of acid production over the circadian cycle. Moreover, H2RAs have the relevant drawback of 
tolerance development, which generally occurs within two weeks of daily dosage. Finally, 
their antisecretory action is impaired in post-prandial periods, because meals are one of the 
most powerful stimulants of acid secretion, but this effect is mediated by gastrin, which is not 
blocked by H2RAs. 
The subsequent recognition that H+-K+-ATPase is the final step in the complex process 
of acid secretion led to the development of a new class of drugs, the proton pump inhibitors 
(PPIs), which are targeted at blocking specifically this enzyme. Conversely from H2RAs, PPIs 
are able to control both basal and meal-stimulated acid secretion and produce a more 
complete and longer-lasting acid suppression, so that their pharmacodynamic effect is 
maintained for 16-18 hours (4), thus permitting the use of a single daily dose. Furthermore, 
they do not present the phenomenon of tolerance due to the lack of receptorial inhibition (5). 
As result of the above-mentioned better pharmacological properties, PPIs have rapidly 
become the first-choice therapy in patients with acid-related disorders, replacing almost 
Ac
ce
pte
d M
an
us
cri
pt
 4
completely H2RAs. The market of these drugs has progressively increased to the point that it 
is estimated that over 113 million PPI prescriptions are filled globally each year in the USA 
and this, together with over-the-counter (OTC) use, accounted for over 13,6 billion dollars 
worldwide in 2009 (6). 
It must also be stressed that the introduction of generic PPIs into the market has 
contributed to increase remarkably PPI prescriptions (7). In addition, as PPIs are now 
available as OTC in many countries, patients can have free access to them and tend to take 
these drugs for long periods of time without seeking any medical attention (8).  
However, the endless expansion of the PPI market has risen many concerns about the 
possible misuse of these drugs, which has created important problems for many regulatory 
authorities of various countries in both western and eastern countries. The two major issues 
are represented by the excessive costs of therapy for both patients and governments and the 
potential risk for iatrogenic harm due to adverse events related to these active and powerful 
drugs and to the unavoidable drug-to-drug interactions in patients taking multiple 
medications for concomitant diseases (9). 
In relation to the above considerations, in the last years there has been a mounting 
number of reports linking the chronic use of PPIs to serious adverse reactions: gastric 
carcinoids, hip fractures, hypomagnesemia, nutritional deficiences, increased incidence of 
cardiovascular events, enteric infections, most notably Clostridium difficile diarrhea, 
community-acquired pneumonia, chronic kidney disease and dementia (10). Obviously, the 
above publications in prestigious international medical journals have contributed to produce 
alarmism in physicians and panic in many patients who are familiar with web navigation.  
2. Aims and methodology of  the review 
In keeping with the above reflections, a review on the appropriate use of PPIs seems to be 
useful in order to emphasize the right indications clearly established for these medications 
and to highlight the most frequent reasons for their misuse in order to reduce their dangerous 
overutilization. To provide a summary of current information on the appropriate use and the 
misuse of PPIs , we took into account the guidelines published in english medical literature 
and the results of many clinical trials on the treatment of upper digestive disorders and the 
related meta-analyses and systematic reviews. In order to identify relevant studies, a 
computerized (Medline) and manual literature search was performed during the period from 
1977 to the end of 2017, with particular focus on the past 15 years. We used the following 
terms : acid-related diseases, GERD or GORD, gastroesophageal reflux disease, acid reflux, 
NERD, non-erosive reflux disease, hypersensitive esophagus, reflux hypersensitivity, 
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functional heartburn, esophageal pH-metry and impedance-pH testing, Barrett’s esophagus, 
eosinophilic esophagitis and PPI responsive esophageal eosinophilia (PPI-REE), Helicobacter 
pylori infection, duodenal ulcer, H. pylori-negative duodenal ulcer, NSAID-induced ulcer, 
iatrogenic gastric ulcer, acid hypersecretory conditions, Zollinger Ellison syndrome (ZES), 
functional dyspepsia, NSAID-induced dyspepsia, stress ulcer, critically ill patients, intensive 
care units (ICUs), treatment and prevention of acid-related disorders, overutilization or 
overprescrition of PPIs, overuse or misuse of antisecretory drugs, costs of overprescribing 
PPIs. The above terms were used alone or in combination with the following ones : 
pathophysiology, treatment, management, PPIs, proton pump inhibitors, H2-blockers, H2 
receptor antagonists, potential harms, adverse events, documented benefits, inappropriate 
prescription, cost-effectiveness, PPI expenditure. We critically reviewed all full-text papers 
and relevant abstracts published in english language. Moreover, the reference lists of the 
various contributions were searched to identify any additional studies that have been missed 
during the process. 
3. Approved indications for PPI therapy  
PPI therapy is indicated in the well defined clinical conditions reported in table I, 
according to the Food and Drug Administration (FDA) in USA (11) and the National Institute 
for Clinical Excellence (NICE) in UK (12). 
4.1 Healing of erosive esophagitis and its maintenance 
Excessive acid exposure in the distal part of the esophagus has been found in 75%-
90% of patients with erosive esophagitis and, from a pathophysiological point of view, this is 
due to multiple factors : an impaired function of the lower esophageal sphincter which 
presents more inappropriate relaxations than normal, a reduced esophageal clearance of 
refluxed material, and a delayed gastric emptying in up to 40% of cases (13). Furthermore, 
the presence of hiatal hernia does favor reflux, even though this is only true for those longer 
than 2 cm (14). The final consequence of these multiple motor abnormalities is that more acid 
lies in the wrong place, that is in contact with esophageal mucosa and this phenomenon 
explains the excellent short-term results achieved with PPIs in healing mucosal lesions. In 
keeping with the meta-analysis by Chiba et al (15), about 85% of patients treated with PPIs 
had complete healing at 8 weeks compared with 52% of those receiving H2RAs and 
subsequent reviews were able to confirm these remarkable results (16), which are clearly 
linked to the greater and longer-lasting acid suppression provided by the inhibition of gastric 
proton pumps. 
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However, GERD is a chronic relapsing disorder, because PPIs do not modify the 
multiple underlying motor alterations sustaining the disease pathogenesis and six months 
after stopping PPI therapy only 10% of patients with erosive esophagitis are still in remission 
(17). So, the prevention of recurrences represents a relevant aim of therapy in patients with 
erosive esophagitis. Vigneri et al (18) were the first Authors to show that once daily dose of 
omeprazole 20 mg was able to maintain 80% of patients with erosive esophagitis free from 
mucosal lesions after 12 months of continuous treatment and this drug was significantly 
superior to both ranitidine and cisapride. The same result was later obtained with 
lansoprazole (15 and 30 mg once daily), which proved to be capable of keeping about 80% of 
patients with erosive esophagitis in remission at 1 year (19). Therefore, PPIs are useful as 
maintenance therapy in order to prevent recurrences of both symptoms and mucosal lesions 
in patients with erosive esophagitis, particularly in those with the most severe forms (from B 
to D, according to the Los Angeles classification).  
4.2 Non erosive reflux disease (NERD) 
In recent years we have realized that GERD is far more complex than previously 
thought as erosive esophagitis represents only about 30% of patients with GERD and the 
remaining 70% pertain to the category of NERD, in whom no esophageal lesions are detected 
by endoscopy (20). Obviously, in this group symptom relief is the main goal of therapy and, 
accordingly, this aim combined with the improvement of quality of life has become the mirror 
of PPI effectiveness in the majority of GERD patients. 
Furthermore, the modern application of 24-hour impedance-pH monitoring, which 
permits to distinguish acid from non-acidic refluxes (21), has allowed us to understand that 
NERD patients are greatly heterogeneous from a pathophysiological point of view and three 
distinct subgroups of them can be identified : a) true NERD with excess of acid in the 
esophagus b) hypersensitive esophagus to acid or non-acid refluxes with normal esophageal 
acid exposure and positive symptom-reflux association c) functional heartburn (FH), which is 
a category no more pertaining to the GERD realm, because there is neither excess of acid in 
their esophagus nor positive correlation between typical symptoms and reflux episodes of 
any type registered by impedance-pH testing (22). 
In relation to the above stratification, it is clear that PPIs can be beneficial only in case 
of true NERD and hypersensitive esophagus to acid, whereas they do not work in patients 
with hypersensitive esophagus to non-acidic reflux and in those with FH, where acid does not 
play any pathogenetic role. In fact, the event of PPI-refractory heartburn is more common in 
NERD than in erosive esophagitis and occurs in about 20%-30% of cases (23). In order to be 
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sure that they are true PPI resistant patients, we have first to check whether they are 
compliant and adherent to treatment.  There are several studies, indeed, showing that only 
27% of patients assume these drugs correctly about 30 minutes before breakfast as once daily 
dose (24). As PPIs are able to control better daytime than nighttime acid secretion (25), in 
case of persistent and severe nocturnal symptoms, it is recommended to fraction the daily 
dose of them into two separate administrations, one before breakfast and the other before 
dinner, in order to achieve a more prolonged pharmacodynamic action up to the first hours of 
the night (26). Several reviews and meta-analyses (27) have confirmed that the various PPIs 
have almost equivalent efficacy in relieving satisfactorily symptoms of GERD in the short term 
(4-8 weeks). Obviously, the use of PPIs is inappropriate in patients with esophagus 
hypersensitive to non-acidic reflux and in FH and therefore these two last conditions require 
other therapeutic measures, mainly pain modulators (20). 
Also NERD patients tend to relapse up to 75% of cases six months after stopping acute 
therapy (17) and therefore a long-term treatment is necessary even in them.  This 
maintenance therapy for preventing symptom recurrence in NERD can be continuous in the 
the few cases with frequent recurrences or on demand in the majority of patients. On demand 
therapy is defined as the administration of drugs in response to symptoms with their 
discontinuation after symptoms are relieved and represents an attractive therapeutic option, 
because of cost-effectiveness and patient convenience. Many randomized clinical trials have 
shown the satisfactory success of the two above-mentioned  long-term therapeutic 
approaches in NERD patients (16,27). 
 
4.3 GERD with extra-esophageal symptoms    
Many papers have reported that GERD can present with extra-esophageal symptoms, 
such as hoarseness, chronic cough and asthma (28), although the causal relationship between 
these respiratory symptoms and reflux episodes remains highly controversial. Indeed,  anti-
reflux therapy with PPIs has been shown to be not superior to placebo in many of these 
patients, unless the relationship between GERD and atypical symptoms has been clearly 
proven by functional testing or concomitant typical symptoms are complained by patients. In 
fact, a recent review (29) suggests a therapeutic benefit by acid suppressing drugs in patients 
with chronic cough and this advocates a rigorous patients’ selection that could allow the 
identification of a patients’ subgroup likely to be PPI responsive. Conversely, no systematic 
reviews or meta-analyses showed any significant success of PPI therapy over placebo in 
patients with chronic laryngitis (30). Moreover, asthma and GERD can often coexist as 
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abnormal reflux has been found in 40%-90% of cases (31). However, a Cochrane review (32) 
has denied any benefit from PPIs compared with placebo and only a more recent study has 
shown that asthma responds in patients with proven reflux and nocturnal symptoms (33). 
Nevertheless,  in many cases the origin of extra-esophageal manifestations is multifactorial 
and an evident responsability of abnormal reflux cannot be documented even by means of 
modern sophisticated functional examinations (34). As the use of PPI doses higher than the 
standard ones and for longer duration than usual are suggested in these patients according to 
international guidelines, the efforts should be addressed to identify people with reasonable 
atypical symptoms–GERD association before embarking on a costly and prolonged PPI 
treatment.  
4.4 Esophageal strictures and Barrett’s esophagus  
The incidence of esophageal strictures has decreased in the last two decades and this 
decline was associated with a marked increase in the use of PPIs. In fact, lansoprazole 30 mg 
once daily resulted in fewer dilatations and a higher proportion of dysphagia-free patients 
than ranitidine 300 mg b.i.d. (35). 
Barrett’s esophagus is the replacement of normal squamous epithelium of the distal 
part of the esophagus with columnar metaplasia and is the most important complication of 
GERD, because it is considered as a pre-cancerous lesion. It is associated with the maximal 
acid exposure compared with the other forms of this disease, so that the use of powerful 
antisecretory therapy with PPIs has a strong rationale. However, the results of medical 
treatment with these drugs has provided conflicting findings in terms of length reduction of 
intestinal metaplasia, whereas two retrospective (36,37) and one prospective (38) studies 
have shown that PPIs may decrease its progression to adenocarcinoma, in that the rate of 
dysplasia development is reduced significantly in PPI-treated than in non-PPI-treated patients 
with Barrett’s esophagus. This outcome is certainly more important than the simple reduction 
in length of intestinal metaplasia and supports the use of long-term PPIs in order to prevent 
the transformation of intestinal metaplasia into dysplasia and neoplasia. As further 
confirmation of this beneficial effect,  it has been recently published a paper reporting the 
results of the eagerly awaited AspECT study, which has recruited 2257 patients with a median 
follow-up and treatment duration of 8-9 years (39).  It showed that high-dose PPI and aspirin 
chemoprevention therapy, especially in combination, significantly and safely improved 
outcomes in terms of  high-grade dysplasia, esophageal adenocarcinoma and all-cause 
mortality in patients with Barrett’s esophagus.  
4.5 Eosinophilic esophagitis (EoE)  
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EoE is a chronic immune-mediated inflammatory disorder, defined symptomatically by 
esophageal dysfunction and structurally by histological eosinophilic-predominant infiltrate 
(40). Esophageal eosinophilia is not limited to the distal part of the organ as in GERD and is 
frequently associated with serious motor alterations leading to dysphagia and food impaction 
(41). Although these patients can benefit from some antigen-free diets or topical 
corticosteroid therapy, some 30%-50% of them respond to twice daily PPI therapy (42). PPI 
responsive esophageal eosinophilia (PPI-REE) is considered a phenotype of EoE responding 
to PPIs, but recent studies have shown its similarity to GERD (43). It cannot be excluded, 
however, that the reason for the benefit of PPI therapy in this group of EoE patients can be 
due to effects other than the antisecretory action, namely their documented anti-
inflammatory activity (44).  Indeed, both in vitro and in vivo investigations suggest that  the 
anti-inflammatory effect of these drugs can be responsible for the improvement of the 
disease, being they capable of inhibiting the Th2 allergic pathway (45).  Anyway, international 
guidelines indicate PPIs as first-line treatment of EoE and other effective alternatives, such as 
diet and topical steroids, should be used as second-line measures, because at present there 
are not criteria able to predict a good response to PPIs in part of these patients. 
4.6 Eradication of H. pylori infection 
A huge medical literature has clearly shown that chronic gastritis and most peptic 
ulcers have to be considered nowadays as infectious diseases, due to H. pylori which is a germ 
with an elective tropism for gastric mucosa (46). Indeed, many studies have confirmed that 
the eradication of this infection is able to cure chronic gastritis with good functional recovery 
of gastric acid secretion and to promote healing of ulcer with permanent disappearance of 
both recurrences and complications (47).  
Different therapeutic schemes have been proposed over time and many of them 
include two antibiotics and a PPI given in two standard daily doses for 7-14 days (48). So, 
PPIs represent a key component of any currently adopted regimen for H. pylori eradication 
and many clinical trials have shown that it is possible to obtain rates of success as high as 
80%-90%  (49). As these rates tended to diminish in last years, mainly due to the 
development of clarithomycin resistance, recent Consensus statements suggest the use of 
quadruple regimens containing also bismuth as powerful drug against H. pylori (50). 
However, PPIs remain the mainstay of anti-Helicobacter therapy also in these more complex 
regimens.  
4.7 H. pylori-negative peptic ulcers 
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Although it is well acknowledged that H. pylori is the cause of peptic ulcer, particularly 
duodenal ulcer, an increasing number of ulcer patients do not bear this germ (51). These H. 
pylori-negative ulcers have been reported to be higher in USA and in Australia (20%-50%) 
than in Europe (52). The precise cause of these ulcers is unknown, but there is some evidence 
that a certain number of them is due to the unrevealed use of aspirin or NSAIDs (53). In the 
other cases the pathogenetic role of acid cannot be excluded, in that high basal and peak acid 
outputs have been found in duodenal ulcers relapsing despite H. pylori eradication (54). So, 
not only NSAID-induced ulcers can be treated with PPIs, but also idiopathic ulcers seems to 
benefit from acid-lowering drugs that need to be continued in the long term in order to 
maintain the ulcers healed (55). 
4.8  NSAID/COXIB-induced dyspepsia   
Dyspeptic symptoms can develop within the first few days of starting a NSAID/COXIB 
therapy and occur even with the first dose of these drugs (35). They can appear in the absence 
of any mucosal gastric lesion in about 15% of cases and the pathogenesis is not fully 
understood. However, a short course (4-8 weeks) of PPIs has been shown to control these 
symptoms adequately (56). 
4.9  Healing of NSAID-associated gastric ulcers and treatment of ulcer bleeding 
NSAIDs are among the most widely used classes of drugs and are very effective in 
controlling pain deriving by various inflammatory conditions. However, their success is 
associated with a very large number of adverse events in the gastrointestinal tract, 
particularly in the gastric mucosa. Indeed, an altered mucosa defense in the presence of a 
normal or decreased acid secretion seems to be the major culprit (1). In fact, despite lower 
acid profiles in the setting of gastric ulcers, a weak mucosa is fundamental to explain the effect 
of acid as secondary actor of the damaging process. Accordingly, it has been shown that the 
administration of NSAIDs, mainly diclofenac, for one month in patients with rheumatoid 
arthritis increases significantly intragastric acidity compared with baseline levels as likely 
result of blocking the antisecretory effect of prostaglandins, which are a well known target of 
NSAID therapy (57). In relation to this ancillary role of acid on a weakened mucosa, PPIs given 
for 4-8 weeks are able to provide ulcer healing, as shown in many randomized clinical trials 
(58).  
The presence of multiple risk factors greatly increases the risk of ulcer complications, 
such as bleeding, as reported in table II. Among them, the most important are prior history of 
complicated ulcer and the age > 65 years. The relevance of previous episodes of ulcer 
complications is obvious, while advancing  age has been shown to increase the risk of 
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bleeding by about 4% per year, probably because of the presence of other factors and, among 
them, the role of concomitant H. pylori infection, which is frequently found  in elderly people,  
cannot be dismissed (35). So, the eradication of the germ should be pursued and can be 
particularly beneficial when starting treatment with NSAIDs or aspirin in patients with 
history of prior ulcer (59). 
Although endoscopy remains the most useful therapeutic intervention to stop bleeding, 
the concomitant use of PPIs, possibly given both orally or intravenously  before endoscopy, 
has the advantage of downgrading the stigmata of recent haemorrhage, thereby reducing the 
need for endoscopic hemostatic procedures, as confirmed by several meta-analyses (60). All 
the randomized controlled trials have shown that PPIs are much more effective than H2RAs in 
both treating and preventing gastroduodenal lesions (61), due to their greater degree and 
longer-lasting duration of acid inhibition. In fact, the objective of medical therapy for bleeding 
ulcers is to maintain a high intragastric pH (> 6 units) in order to promote platelet 
aggregation as well as the formation and stability of the clot inside the stomach (62), in that it 
is well known that platelet function is impaired at low pH values and pepsin promotes clot 
lysis below pH 5.0 (63).  
Current guidelines (64) recommend the adoption of an intravenous bolus followed by 
a continuous infusion of PPIs, but a recent meta-analysis (65) showed that the efficacy of 
continuous or intermittent infusion does not differ. However, the Peptic Ulcer Bleed study, 
involving 91 hospital emergency departments of 16 countries, showed that high-dose 
intravenous esomeprazole (80 mg in bolus followed by 8 mg/h infusion for 72 hours), given 
after successful endoscopic therapy in high-risk patients, reduced recurrent bleeding and kept 
a clinical benefit up to 30 days, while patients continued to take also orally esomeprazole 40 
mg once daily (66).  
4.10  Prophylaxis of  NSAID-associated gastric ulcer 
NSAIDs and aspirin are often prescribed chronically, especially in elderly subjects, for 
various important reasons, the  latter drug mainly to prevent cerebral and cardiovascular 
ischemic events. Although they are very effective medications in this field, there is a great risk 
of complication development, particularly in the upper digestive tract. This risk is augmented 
in those patients bearing the already mentioned predisposing conditions listed in table II.  
It must also be stressed that, although COX-2 selective NSAIDs (COXIBS) present a 
better safety profile than the traditional non-selective ones, they reduce the risk of gastric 
lesions by only 50% (67) and therefore the association of them with a PPI can be necessary, 
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particularly in patients with the well known above risk factors in order to prevent ulcer 
formation and its complications. 
International guidelines recommend the use of continuous PPI co-therapy in order to 
avoid gastric ulcer formation and gastrointestinal bleeding occurrence on the basis of the 
positive results of many trials showing that the combination of PPIs and NSAIDs or aspirin 
decrease the number of ulcers (68) and the recurrence of ulcer bleeding also in those taking 
the apparently safe low-dose aspirin (69). 
4.11  Treatment of Zollinger-Ellison syndrome  
This is the best characterized acid hypersecretory disorder and is caused by the tumor 
gastrinoma producing a large amount of gastrin, which in turn stimulates a remarkable acid 
hypersecretion (70). PPIs are the drug of choice for the medical treatment of ZES, but 
relatively high doses (3-4 times the standard dose) are required in comparison with those 
usually adopted for the other acid-related conditions (71). In fact, it is important that acid 
secretion is reduced below 10 mEq/h or below 5 mEq/h in post-surgical stomach to avoid 
ulcer recurrence and complications (72).  
In patients who have undergone successful gastrinoma resection, PPIs may be still 
required because a hypersecretory status is kept in at least half of them (72). When surgical 
tumor removal is not possible, antisecretory therapy must be continued indefinitely.  
4.12  Prophylaxis of stress ulcers in critically ill patients 
Stress ulcer is an acute condition occurring in patients admitted in intensive care units 
(ICUs) and is commonly located in the proximal stomach. It seems to be the result of an 
ischemic damage reducing the mucosal defense, thereby acid acts only as a secondary factor. 
Current guidelines approve the use of PPIs as stress ulcer prophylaxis (SUP) in ICU patients at 
high risk of gastrointestinal bleeding, such as those who require mechanical ventilation for 
more than 48 hours or those with coagulopathy, who have an OR of 15.6 and 4.3, respectively 
(73). Several large meta-analyses found that the risk of bleeding in ICUs is reduced by about 
60% in patients receiving SUP compared with those treated with placebo or no prophylaxis 
(74,75). Therefore, SUP  has become the standard of care in the ICUs, sometimes irrespective 
of the presence of risk factors.  
 
 
4.13  Functional dyspepsia    
Dyspepsia is a common condition seen in daily clinical practice of both general 
practitioners and gastroenterologists. It is characterized by one or more symptoms referred 
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to the central upper part of the abdomen and, when endoscopy is negative and the intake of 
NSAIDs or aspirin has been excluded, the diagnosis of functional dyspepsia (FD) can be made. 
According to Rome IV criteria for functional gastrointestinal disorders (76), FD is subdivided 
into epigastric pain syndrome (EPS), including symptoms such as epigastric pain or burning, 
and post-prandial distress syndrome (PDS), including other symptoms such as epigastric 
fullness and early satiation. However, it is not rare that the symptoms of the two forms 
overlap.  
Although acid hypersecretion does not exist in these patients (77), the lack of clear 
mechanisms originating the above symptoms lead physicians to adopt PPI therapy as the 
most frequent therapeutic attempt, particularly in cases of EPS (9,35). So, the success of PPIs 
is scant and varies from 10% to about 30%, according to several meta-analyses and the 
number needed-to-treat ranges from 10 to 15 (78,79). There is no significant benefit from 
PPIs in PDS patients (35). So, considering the unsatisfactory results of PPIs in FD and the 
absence of other successful medications, a short-term, low-dose PPI treatment can be 
suggested in these patients, providing that there is a regular re-evaluation by physicians in 
order to avoid chronic treatment (80).  
 
5.  Misuse of PPIs  
 There is no doubt that PPI therapy has revolutionized our approach to the 
management of the above-mentioned acid-related conditions and the results have been very 
good and significantly superior to those achieved with H2RAs. 
Nevertheless, PPI use continues to grow every year in almost all western and eastern 
countries (81) and this calls into question the role of their misuse in both hospitals and 
primary care setting. In fact, it has been calculated that more than 50% of PPIs are prescribed 
inappropriately in general medical wards and in general practitioners’ practice (9) and these 
rates are worrying, because they suggest that PPI use is often devoted to indications different 
from those recommended by expert consensus statements. 
5.1 Misuse of PPIs in the hospital setting 
The main reasons for PPI misuse in both hospital and primary care settings  are 
reported in table III. Several investigations have analysed the rate of PPI overprescription in  
hospitalized patients. Reid et al (82) performed a retrospective review from two databases of 
university-affiliated hospitals in Colorado, taking into consideration randomly selected adult 
patients aged 18 to 90 years admitted for medical services. Appropriateness of PPI therapy 
was determined using International Classification of Diseases, 9th revision (ICD-9) codes. 
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They found that 40% of patients in one databse and 14% of those in the other were 
prescribed PPIs during hospitalization. Adjusting data according to possible administrative 
errors, resulted that > 50% of cases failed to meet proper indications for PPI therapy. So, it is 
evident from this study that there is overuse of PPIs in US hospitalized patients, although the 
Authors recognized important limitations in their analysis. A further study conducted by 
Thomas et al (83) evaluated appropriate initiation of PPIs during hospitalization using again 
ICD-9 codes.  PPI therapy was only considered appropriate if the patient was taking PPIs prior 
to hospitalization or if its use was consistent with diagnoses. A total of 20,197 (68.8%) 
patients were categorized as inappropriate users of PPI therapy. Moreover, when comparing 
critically ill patients versus medical patients, there was no statistically significant difference 
found with respect to inappropriate use (68.7% and 68.9%, respectively). Evaluation of PPI 
misuse was continued over 4 years, although it decreased slightly during this time. However, 
there was no significant difference over time. Similarly to the already mentioned study by 
Reid et al,  the accuracy of results may have been limited by the retrospective design of the 
investigation. However, the findings they reported are worrying and cannot be overlooked.  
Gupta et al (84) evaluated retrospectively the inappropriate prescription of acid 
suppressive therapy, mainly PPIs, during hospital admission and at hospital discharge over a 
3 month period in a sample of 279 patients. They found that an appropriate use of PPIs 
according to current guidelines and FDA approval was identified only in 27% of patients who 
were prescribed acid suppressant drugs upon admission to hospital and 69% of those 
receiving inappropriate therapy were discharged with it. The most common reasons for this 
uncorrect prescription were SUP in low risk patients and ulcer prophylaxis in patients taking 
steroids alone or anti-coagulants without any risk factor. Despite the usual limitation of a 
retrospective study, the high rate of inappropriate PPI continuation upon discharge must be 
emphasized, because this illustrates the need for more thorough medication reconciliation 
prior to discharge.  
Heidelbaugh et al (85) conducted a retrospective chart review over a 4-month period 
at a large university hospital on adult non-ICU patients to assess the practice of prescribing 
SUP. They found that of the 391 patient admissions prescribed SUP with almost exclusively 
PPIs, no patient met the criteria for SUP according to the guidelines and 54% of them were 
discharged on a prescription for acid suppressant therapy.  
Finally, Zink et al (86) performed a retrospective chart review of general medical 
patients admitted to a teaching hospital over a 6-month period. Patients received an H2RA or 
a PPI. Appropriate indications were defined as an FDA-approved use or an indication 
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supported by medical literature. Out of 324 patients included in the review, 128 (40%) were 
initiated on acid suppressant therapy with an appropriate indication, whereas 196 (60%) 
were inappropriate and 34% of them were discharged on the medication.  
Overall, many studies have demonstrated high rates of inappropriate use of PPIs in the 
inpatient setting. All these studies are limited by their retrospective nature, but they confirm 
that the phenomenon is highly represented and the continuation of PPI therapy upon 
admission remains frequent, so this wrong behaviour must be discouraged in order to 
decrease costs and potential for serious adverse events and drug-to-drug interactions. The 
most common reason for this PPI misuse is SUP in low-risk patients, but ulcer prophylaxis in 
patients taking steroids alone or anti-coagulants without risk factors are also frequent 
inappropriate indications. 
5.2 Misuse of PPIs in the primary care setting  
In the primary care setting, the continuation of PPI intake after patients’ discharge 
from hospitals and the absence of doctors’ periodic review in subjects taking PPIs chronically 
are the main causes of inappropriate use of these drugs (9,87). Rather surprisingly, too often 
PPIs are perceived by doctors themselves as a harmless and relatively inexpensive remedy for 
any digestive trouble which a patient has to encounter throughout her/his life. Indeed, we 
have above stressed that the quantity of patients who start PPIs after hospital admission is 
very high and the reasons for this therapy are often inconsistent and not related at all  to a 
real pathogenetic role of acid. Interestingly, one study (88) has shown that the strongest 
factor associated with the inappropriate continuation of PPIs after hospital discharge was the 
intake of these drugs already before hospitalization and the lack of any critical reflection on 
their use during the inpatient stay, so that hospital doctors  continue to prescribe these drugs 
at the discharge and general practitioners think that the prescription is correct and must be 
pursued in the long term.  
FD represents another clinical area at great risk of PPI overpresciption, particularly in 
the long term and in those with the PDS variant. It is well known that many general 
practitioners prescribe these drugs to their patients indefinitely without any periodic re-
evaluation of whether there is really a continuing need to take this therapy or it is possible to 
reduce the dosage or to stop them at all, in order to avoid an unuseful overprescription. 
Moreover, functional dyspeptic symptoms are frequently associated with functional 
heartburn (89) or irritable bowel syndrome (90) and physicians must evaluate accurately the 
existence of these possible combinations, because they are predictive of poor response to PPI 
therapy (91).  
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In patients taking steroids alone for whatever clinical condition, mucosal protection 
with a PPI is not routinely indicated (35,92), unless they are associated with concomitant 
NSAID drugs. Indeed, several studies (93,94) failed to demonstrate an association between 
corticosteroid use and risk of ulcer formation and its complications after adjustment for 
confounding factors. A meta-analysis also failed to show any significant risk for gastric and 
duodenal ulcers in patients receiving corticosteroid treatment compared to controls (92) and 
a systematic review of available meta-analyses in this field confirmed the same conclusion 
(95). In summary, no evidence currently supports the prophylactic use of PPIs in patients 
taking corticosteroids alone in order to prevent the development of peptic ulcers in the 
gastroduodenal tract. 
NSAID/ASA and COXIB use in patients younger than 65 years and without other 
already-mentioned risk factors, gastroprotection with PPIs is not advised. In fact, Laine et al 
(96) found that older age increases the risk of developing a clinical gastrointestinal adverse 
event in individuals taking COXIBs or non-selective NSAIDs by stratifying 8,076 patients with 
rheumatoid arthritis into three subgroups of different age. In particular, the number needed 
to treat (NNT) to produce an adverse reaction was 10 in patients > 75 years old, 25 in patients 
65-74 years and 66 in those < 65 years.  
More recently, the synergistic role of NSAIDS and selective serotonin re-uptake 
inhibitors (SSRIs) has been highlighted, because it seems that there is a marked decrease in 
serotonin platelet content with consequent impairment of their aggregation in response to 
injury and the consequent prolongation of bleeding time (97). So, the association of NSAIDs 
and SSRIs can alter the hemostatic process and promote more severe bleeding and thus 
should be avoided; if this is not possible, the adoption of PPI therapy from the beginning of 
this combination treatment is highly recommended.   
Also the administration of anti-coagulant compounds, such a slow molecular weight 
heparin or warfarin, in subjects without any risk factor is not an indication to associate PPI 
therapy, because these drugs are not directly gastrotoxic (9). A recent paper (98) has clearly 
demonstrated that  PPI co-therapy had no significant protective effect for warfarin patients 
not using concomitant anti-platelet drugs or NSAIDs compared with those not taking PPIs, 
thus confirming that only the combination with gastrotoxic drugs enhances the rate of 
gastrointestinal bleeding and the need for hospitalization and then it requires PPI protection. 
When acenocoumarol is used as anti-coagulant, some caution is needed when prescribing 
PPIs (in particular omeprazole, esomeprazole and lansoprazole), because of potential 
overcoagulation most likely due to facilitated gastric absorption of warfarin (99), whereas no 
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demonstrated interaction exists between PPIs and the novel oral anti-coagulants (35). Also 
ticlopidine or clopidogrel given alone in patients without risk factors do not require PPI use, 
which is mandatory only when the latter is associated with aspirin in the secondary 
prevention of cardiac ischemic attacks, because the  combination of the two anti-platelet 
drugs is associated with serious harm of gastrointestinal bleeding (100). PPI co-therapy is 
able to reduce the risk of GI bleeding in these patients, although the well known interaction  
between them and clopidogrel at the level of CYP 2C19 in the liver with consequent lesser 
anti-platelet effect (101). PPIs that lack inhibition of hepatic CYP 2C19 (i.e. pantoprazole or 
rabeprazole) might be preferred in clopidogrel users (102). 
In patients with liver cirrhosis and portal hypertension there is no benefit from PPI 
use, which is frequently adopted in daily clinical practice to prevent bleeding from 
hypertensive gastropathy, because it has been shown that their circadian intragastric acidity 
is significantly lower than in normal subjects (103). More importantly, there is some evidence 
that PPI use could be associated with development of spontaneous bacterial peritonitis (104). 
Some studies have also shown that both a low income and a low educational level are 
associated wiht prolonged utilization and misuse of PPIs (105) and therefore other non-
medical reasons sustain this phenomenon. In fact, a nationwide cohort study carried out in 
Denmark (106) on patients taking for the first time PPIs and followed up for 10 years showed 
that the long-term utilization of these antisecretory drugs was significantly associated with 
low salary and low education, after adjusting the analysis to avoid other confounding 
variables. Also another Canadian study confirmed that living in areas of low socio-economic 
status was a predictor of a high and often incorrect consumption of PPIs on a chronic basis 
(107).  
5.3 Consequences of PPI overuse/misuse.  
The above overuse/misuse of PPIs is obviously responsible for a relevant increase of  
the costs of PPI therapy, up to the point that 2 billion pounds are being spent unnecessarily on 
PPIs each year (108). In a US study (85), the estimated cost for 1,034 patient-years treated 
inappropriately with PPIs was 1,566,252 dollars, based on average wholesale price costs. We 
have already mentioned the study by  Thomas et al (83), who reviewed the pharmacy costs 
over a 4-year period of more than 20,000 patients receiving PPI therapy inappropriately after 
hospital admission and found that the unuseful global expense was approximately 3,000,000 
dollars.  
 Finally, the overprescription of PPIs, especially in the elderly, can induce the 
appearance of various adverse events, as reported in many recent alarming publications 
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(10,109). However, many of these studies are observational and retrospective and then must 
be interpreted with great caution. In reality, if PPI therapy has an appropriate indication, the 
adverse reactions are confined within 1%-3%, a level compatible with that of any active and 
effective pharmacological compound (35). Some of them are plausible and predictable, while 
others are idiosyncratic, unpredictable and rare. The most serious harms with chronic PPI 
administration  are represented by hypomagnesemia, enteric infections, mainly those from 
Clostridium difficile in elderly people, and acute kidney disease, such as idiosyncratic 
interstitial nephritis.  
5.4 Discontinuing long-term PPI therapy 
For patients who are taking PPI therapy for unclear indications or symptoms where 
there is little indication for PPI use, the discontinuation of these drugs must be attempted.  
However, the sudden withdrawal of PPIs may cause a marked rise in gastric acid output, a 
phenomenon known as rebound gastric acid hypersecretion. As a consequence, this may 
induce or aggravate upper GI symptoms. Reimer et al (110) were the first to show that 40% of 
healthy individuals who discontinued PPIs after 8 weeks of treatment reported dyspepsia in 
the 4 weeks following withdrawal. Niklasson et al (111) showed that symptoms on PPI 
discontinuation were significantly correlated with the degree of PPI-induced 
hypergastrinemia. In a study in which 78 patients not having a clear indication for PPI use 
were discontinued, nearly two/thirds developed upper GI symptoms within 6 months and 
40% of them had endoscopic findings consistent with their symptoms, mostly mild 
esophagitis (112). So, it seems important to avoid the abrupt withdrawal of PPIs, particularly 
in chronic users, and adopt a strategy aimed at reducing the phenomenon of rebound acid 
hypersecretion. PPI deprescribing can be achieved by stepping down to a lower dose or to an 
intermittent/on demand regimen or by replacing PPIs with a less potent acid inhibitor, such 
as H2 receptor antagonists (113). 
 
5.5  Conclusions 
There is no doubt that PPIs are effective drugs in the management of acid-related 
diseases, both in the short- and in the long-term. They have to be prescribed for the following 
major and universally recognized clinical conditions : treatment of GERD in its various forms 
and complications, PPI-REE as particular subgroup of eosinophilic esophagitis, eradication of 
H. pylori infection in combination with antibiotics, H. pylori-negative peptic ulcers, healing 
and prophylaxis of NSAID-associated gastric ulcers, co-therapy with endoscopic procedures in 
bleeding upper digestive ulcers and the Zollinger Ellison syndrome.  
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The respect of the above guidelines could permit to reduce the high rate of PPI misuse, 
which is associated with increased costs and higher-than-expected incidence of adverse 
events. The major reasons for the misuse of PPIs are the prevention of gastro-duodenal ulcers 
in patients without risk factors and the stress ulcer prophylaxis in non-intensive care units, 
steroid therapy alone, anti-platelet or anti-coagulant treatment in patients without risk of 
gastric injury and the overtreatment of functional dyspepsia.  
6.  Expert commentary 
The advent of PPIs as the most powerful blockers of gastric acid secretion in the last 
thirty years has allowed us to control adequately acid-related diseases, thus minimizing the 
role of surgery in this field. The main indications for PPI use, as acknowledged by the most 
important gastroenterological scientific societies, are represented by the various forms and 
complications of gastroesophageal reflux disease, the eradication of H. pylori infection in 
combination with antibiotics, the short- and long-term therapy of H. pylori-negative peptic 
ulcers, the healing and prevention of NSAID/COXIB-associated gastric ulcers,  the co-therapy 
with endoscopic procedures to control upper digestive bleeding and the medical treatment of 
Zollinger-Ellison syndrome. 
However, the market of PPIs continues to grow in both western and eastern countries 
and there is evidence in many international publications that these drugs are prescribed 
inappropriately in both hospital and ambulatory settings. The main reasons for the misuse of 
PPIs are their administration in patients taking steroids alone, SSRIs alone, NSAIDs/COXIBs 
without risk factors, ticlopidine or clopidogrel or anti-coagulants alone without risk factors, 
the stress ulcer prophylaxis in non-intensive care units, the overtreatment of functional 
dyspepsia, the improper prescription of PPIs during hospital stay and their continuation after 
hospital discharge. 
The major consequences of the misuse of PPIs are the excessive costs of therapy for 
both patients and governements and the risk of adverse events and possible drug-to-drug 
interactions in patients taking multiple medications for concomitant diseases. So, adhering to 
evidence-based guidelines represents the only rational approach to an effective and safe PPI 
therapy. 
In conclusion, international scientific societies and health care authorities should 
develop specific programs aimed at educating and guiding both primary care physicians and 
specialists to the definite indications for PPI therapy and to eliminate unnecessary PPI use, 
thus reducing superfluous government expenditures and potentially serious  adverse events 
in patients.  
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7.  5 year view 
It is not easy to predict the behaviour of PPI market in the near future, but the risk that 
it will expand further remains possible. This continuous growth can be favoured by the 
introduction of generic PPIs into the market of many western countries, because  this 
phenomenon  may help to increase remarkably the PPI prescriptions in terms of chronic 
treatments, unlicensed indications and therapeutic substitutions. In addition, PPIs are now 
available as OTC in many countries and therefore patients can have free access to them with 
the consequence of taking these powerful drugs for long periods of time without seeking any 
medical attention. It must be also highlighted that the overprescrition of PPIs, particularly in 
the elderly, can induce the development of various adverse events, as reported in many recent 
alarming publications. 
In order to reverse this potentially dangerous and costly trend of PPI overprescrition, 
only evidence-based recommedations, which consider the balance between benefits and 
harms, should be followed in every-day clinical practice. Therefore, we believe that 
gastroenterologists, who are the main class of doctors utilizing these drugs, together with  the 
scientific societies  and the regulatory authorities, should plan educational initiatives in order 
to guide both primary care physicians and hospitalists to the correct use of PPIs, according to 
the worldwide published gidelines. 
 
 
8. Key issues 
- PPIs are the best therapy for acid-related disorders 
- The main indications for PPIs are represented by GERD, eradication of H. pylori 
infection in combination with antibiotics, H. pylori-negative peptic ulcers, healing 
and prevention of NSAID/COXIB-induced gastric ulcers and acid hypersecretory 
disorders, such as ZES 
- The market of PPIs continues to grow in many western and eastern countries 
- Many international publications document that the inappropriate use of PPIs 
remains consistently high both in hospital and in primary care settings 
- The main reasons for the misuse of PPIs are the prevention of gastro-duodenal 
ulcers in patients without risk factors, the stress ulcer prophylaxis in non-intensive 
care units, steroid therapy alone, anti-coagulant and anti-platelet treatment in 
patients without risk of gastric injury and the overtreatment of functional 
dyspepsia 
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- The two main concerns pertaining to the misuse of PPIs are drug expenditure and 
risk of adverse events 
- Education is the key to guide hospital doctors and general practitioners to the 
correct use of PPIs, according to worldwide published guidelines 
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Table I. Internationally approved indications for PPI therapy 
- Healing of erosive esophagitis and its maintenance 
- Non-erosive reflux disease (NERD) with excess of acid or acid hypersensitivity 
- Gastroesophageal reflux disease (GERD) with ascertained extra-esophageal 
symptoms 
- Complications of GERD, including esophageal strictures and Barrett’s esophagus 
- PPI-responsive esophageal eosinophilia 
- Eradication of Helicobacter pylori infection in combination with antibiotics 
- Treatment of H. pylori-negative peptic ulcers 
- Symptomatic treatment of NSAID-induced dyspepsia 
- Healing of NSAID-associated gastric ulcers and treatment of their bleeding 
- Prophylaxis of NSAID-associated gastric ulcers 
- Medical therapy of Zollinger Ellison syndrome (ZES) 
- Prophylaxis of stress ulcers in critically ill patients, particularly those on prolonged 
mechanical ventilation and presence of coagulopathy 
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- Short-term treatment of patients with functional dyspepsia, particularly those with 
the epigastric pain variant (EPS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table II. Risk factors indicating the need for appropriate prophylaxis with 
PPIs  
- History of ulcer complications, particularly bleeding 
- Age > 65 years 
- Prior ulcer 
- NSAIDs/COXIBs at high doses or in combination with other gastrotoxic drugs or 
anti-coagulants (multiple NSAIDs/COXIBs, steroids, selective serotonin re-uptake 
inhibitors, warfarin) 
- Aspirin use, even at low dosage in elderly patients, or combined with other drugs 
(NSAIDS/COXIBs, steroids, anticoagulants, clopidogrel) 
- Ticlopidine or clopidogrel use in patients at high risk (see above) 
- Acute NSAID/COXIB use in patients taking chronically anti-coagulant or anti-
platelet drugs 
 
Table III. Main causes of misuse of PPI therapy 
- Steroids intake alone 
- SSRIs intake alone 
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- NSAID/ASA/COXIB use in patients < 65 yrs or without other risk factors 
- Low molecular weight heparin or warfarin alone without risk factors 
- Ticlopidine or clopidogrel alone without risk factors 
- Stress ulcer prophylaxis in non-ICUs 
- Wrong diagnosis of acid-related disorder 
- Overtreatment of functional dyspepsia 
- Patients with chronic liver disease and portal hypertension 
- Improper prescription of PPIs during hospital stay 
- Continuation of PPIs prescribed inappropriately upon hospital discharge 
- Absence of regular doctors’ re-evaluation of their patients assuming chronically PPI 
therapy 
